Sign in

ARIA on NASDAQ

ARIAD Pharmaceuticals

Logo: ARIAD Pharmaceuticals, Public domain, via Wikimedia Commons5

Defunct oncology company

ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients.3 It was founded by Harvey Berger.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1991Founded1

Compare with another stock.

  • TickerARIA on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersCambridge1
  • Websitewww.ariad.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address125 Binney Street, Cambridge, Ma 021426
  • Filer categoryLarge accelerated filer6
  • LEI549300XQ24MXF2Y7K5354
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O The Prentice-Hall Corporation System, Inc., 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 22600544

See how the biggest companies compare on our leaderboards

ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients.3

Corporate structure

ARIAD Pharmaceuticals sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

  • ARIAD Pharmaceuticals Cambridge, Massachusetts, United States
    • ARIAD Pharmaceuticals (United Kingdom) Subsidiary · United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries, stakes and holdings from Wikidata (CC0). Each entity in the chart links to its source.

What it owns

What ARIAD Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$296.7M8 Dec 31, 2015$241.9M8 Dec 31, 2014+22.7%
Accumulated depreciation$42.6M8 Dec 31, 2015$38.8M8 Dec 31, 2014+9.7%
Property and equipment, net$254.1M8 Dec 31, 2015$203.0M8 Dec 31, 2014+25.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$230.9M8 Dec 31, 2015$352.7M8 Dec 31, 2014−34.5%
Marketable securities, current$11.4M8 Dec 31, 2015

Intangibles and goodwill

ItemLatestA year beforeChange
Accumulated amortization$5.1M8 Dec 31, 2015$5.0M8 Dec 31, 2014+0.8%
Finite-lived intangibles, net$899.0K8 Dec 31, 2015$939.0K8 Dec 31, 2014−4.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$1.1M8 Dec 31, 2015$979.0K8 Dec 31, 2014+12.0%
Raw materials$813.0K8 Dec 31, 2015$09 Dec 31, 2014
Work in process$89.0K8 Dec 31, 2015$460.0K8 Dec 31, 2014−80.7%
Finished goods$1.0M8 Dec 31, 2015$979.0K8 Dec 31, 2014+2.9%

The story

Founded by Harvey Berger in 1991.1

ARIAD Pharmaceuticals, Inc. was founded in 1991 in Cambridge, Massachusetts by Harvey J. Berger, M.D. ARIAD raised $46 million as its initial financing in 1992, making it the single highest round of funding in the biotechnology industry at that time. ARIAD filed for an initial public offering through NASDAQ in 1994. ARIAD established its European headquarters in Lausanne, Switzerland.

The company sells and markets its initial drug, Iclusig, through specialty pharmacies and specialty distributors in the United States. In 2016, ARIAD sold its European business and the distribution of Iclusig to Incyte Corp and now receives royalties and other payments from Incyte based on Iclusig sales in the EU. ARIAD also developed two small-molecule drugs, ridaforolimus and rimiducid, and licensed them to companies with complementary technologies.

In July 2015, the company announced it was due to receive up to $200 million through a royalty financing deal with PDL BioPharma. ARIAD is obligated to repay the $200 mm and a predefined interest, with the note being guaranteed by future sales of ponatinib and in some cases, brigatinib.

On February 21, 2014 ARIAD Pharmaceuticals announced the appointment of Sarissa Capital's Alexander J. Denner, Ph.D. to a two-year term on the company's Board of Directors and became ARIAD's second-largest shareholder. In 2016, ARIAD announced that Denner had become the chairman of the board and the company announced the termination of its shareholder's rights plan.

In 2016, the company was ranked #3 on the Deloitte Fast 500 North America list.

Berger retired as chairman and CEO of ARIAD in December 2015 and became Founder, chairman and CEO Emeritus as of January 2016.

From Wikipedia’s article on ARIAD Pharmaceuticals, shared under CC BY-SA 4.0.7

Leadership

Who has led ARIAD Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Harvey Berger2006–2016
  2. Paris Panayiotopoulos2016–2017

Chair

  1. Harvey Berger2006–2016

President

  1. Timothy P. Clackson2010–2017
  2. Paris Panayiotopoulos2016–2017

Chief financial officer

  1. Edward M. Fitzgerald2008–2016
  2. Manmeet Singh Soni2016–2017

Chief operating officer

  1. Richard W. Pascoe2008
1995200020052010201520202025
Board members and other officers (37)

Products and brands

  • ponatinib

Listed on Wikidata.1

Ponatinib (Iclusig)

ARIAD developed Ponatinib (Iclusig), a tyrosine kinase inhibitor for the treatment of adult patients with Philadelphia chromosome-positive [Ph+] chronic myeloid leukemia (CML), and acute lymphoblastic leukemia. On December 14, 2012 the FDA approved ARIAD's leukemia drug Ponatinib for patients with all forms of Ph+ CML or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to or unable to tolerate other tyrosine kinase inhibitors. The drug was temporarily withdrawn from the U.S. market in November 2013 because of the risk of blood clots and severe narrowing of blood vessels. Ponatinib was returned to the market in the U.S. on December 20, 2013 with revised prescribing information, new warnings and a REMS. ARIAD had set up an emergency-access program for Ponatinib, which provided drugs to patients in need during this six-week period. Ponatinib remained on the market in all European countries and was subsequently approved in Japan.

Brigatinib (Alunbrig)

ARIAD’s product pipeline includes brigatinib, an inhibitor of anaplastic lymphoma kinase [ALK] for treating ALK+ non-small cell lung cancer. This drug reported results of its registration trial at ASCO, June 6, 2016, with encouraging results, leading to approval in the U.S. in April 2017. Brigatinib was designated a Breakthrough Medicine by the FDA.

Ridaforolimus (formerly Deforolimus, partnered with Medinol)

Ridaforolimus is an mTOR inhibitor being developed by Medinol Ltd for use in drug-eluting stents for patients with coronary artery disease. Medinol has completed two registrational trials in patients with coronary artery disease, which met its primary and secondary endpoints.

In October 2017, Medinol’s EluNIR drug eluting stent, coated with ridaforolimus, received CE Mark in Europe. In November 2017, it was approved for marketing in the U.S. by the FDA.

Read the full text

Products under development

Various company-sponsored and investigator-sponsored trials are ongoing in several indications, including first line and second line CML, acute lymphoblastic leukemia (BCR-ABL), acute myeloid leukemia (FLT3 inhibitor), non-small cell lung cancer (RET, FGFR), advanced biliary cancer with FGFR2 fusions and other cancers with activating mutations involving the following genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, and KIT.

Rimiducid

Rimiducid is an investigational chemical dimerizer being developed by partner, Bellicum Pharmaceuticals and is in Phase 3 clinical trials.

AP32788

AP32788 is a tyrosine kinase inhibitor of solid tumors with EGFR and HER2 activating mutation and began Phase 1/2 testing in the second quarter of 2016.

From Wikipedia’s article on ARIAD Pharmaceuticals, shared under CC BY-SA 4.0.7

Subsidiaries and ownership

Owners

Subsidiaries

  • ARIAD Pharmaceuticals (United Kingdom)

From Wikidata.1

Timeline

  1. Jan 6, 2016New chief executive Paris Panayiotopoulos becomes CEO10
  2. Mar 10, 2006New chief executive Harvey Berger becomes CEO11
  3. 1991Founded Founded1

SEC filer profile

How ARIAD Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARARIAD PHARMACEUTICALS INC2
  • CIK0000884731
  • Filer statusLarge accelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • Business address125 Binney Street, Cambridge, MA 021422
  • Phone61749404002
  • Shares outstanding194,200,862 as of Oct 31, 201652
  • Public float$1.4B as of Jun 30, 20158
  • On EDGAR sinceMay 8, 19962
  • Filings1,409 in all: 4 (639), 8-K (339), 10-Q (63), SC 13G/A (46), SC 13G (35), 3 (34), DEF 14A (22), 10-K (19)2
    All 52 form types

    424B5 (17), 4/A (16), SC 13D/A (12), ARS (11), CT ORDER (11), S-8 POS (11), 424B2 (10), DEFA14A (10), S-3 (10), S-8 (10), CORRESP (8), UPLOAD (8), 10-K/A (6), PRE 14A (6), S-3/A (6), POS AM (5), SC 14D9/A (5), 10-Q/A (4), 424B3 (4), S-3MEF (4), SC 13D (4), SC TO-T/A (4), 8-A12B/A (3), 8-K/A (3), SC TO-C (3), EFFECT (2), FWP (2), 10-K405 (1), 15-12B (1), 15-12G (1), 25-NSE (1), 5 (1), 8-A12B (1), 8-A12G (1), 8-A12G/A (1), AW (1), NO ACT (1), NT 10-Q (1), POS462B (1), REGDEX (1), S-3ASR (1), SC 14D9 (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Feb 29, 2016
    Quarterly report (10-Q) Nov 8, 2016
    Proxy statement (DEF 14A) Jun 8, 2016
    Latest 8-K (8-K) Feb 16, 2017

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52